News Breaks |
|
|
| September 27, 2012 |
| 10:38 EDT |  | BAYRY | FDA approves Bayer drug to treat colorectal cancer
The FDA announced that it approved Stivarga to treat patients with colorectal cancer that has progressed after treatment and spread to other parts of the body. Stivarga is a multi-kinase inhibitor that blocks several enzymes that promote cancer growth. Stivarga is being approved one month ahead of the product’s prescription drug user fee goal date of Oct. 27, the date the agency was scheduled to complete review of the drug application. Stivarga is being approved with a Boxed Warning alerting patients and health care professionals that severe and fatal liver toxicity occurred in patients treated with Stivarga during clinical studies. Stivarga is marketed by Bayer (BAYRY). |
|
|
News For BAYRY From The Last 14 Days Check below for free stories on BAYRY the last two weeks. |
|
|
| May 24, 2013 |
| 06:05 EDT |  | BAYRY | FDA targets IPhone urinalysis app, Bloomberg reports
 Subscribe for More Information |
|
| May 23, 2013 |
| 06:05 EDT |  | BAYRY | Bayer initiated with an Equal Weight at Morgan Stanley
|
|
| May 20, 2013 |
| 17:20 EDT | | BAYRY | Regeneron,, Bayer, Genentech resolve certain patent disputes
Subscribe for More Information |
|
| 07:28 EDT |  | BAYRY | American Thoracic Society to hold a conference
Subscribe for More Information |
|
| May 17, 2013 |
| 06:33 EDT | | BAYRY | American Thoracic Society to hold a conference
Subscribe for More Information |
|
| May 15, 2013 |
| 11:43 EDT | | BAYRY | Bayer announces FDA approval for Xofigo as CRPC treatment
Subscribe for More Information |
|
|
|
|
|
